Treatment of Depression in Youth With Bipolar Disorders
Terminated
National Institute of Mental Health (NIMH)
Phase 3
1969-12-31
THIS STUDY HAS BEEN DISCONTINUED.
The study is designed to evaluate the safety and efficacy of fluoxetine for treating children
and adolescents with Bipolar Disorder who are experiencing an episode of major depression
while being treated with a mood stabilizer. The study involves a 2-week assessment period.
Patients who are on stable, therapeutic doses of lithium or valproate and continue to have
depression will be randomized to a 12-week treatment of fluoxetine or placebo. Those who
respond favorably to treatment will be followed openly for an 18-week continuation phase.
Treatment and Outcome of Early Onset Bipolar Disorder
Completed
National Institute of Mental Health (NIMH)
Phase 4
2002-08-01
This study will compare the effectiveness in the maintenance of continuing adjunctive
atypical antipsychotic medication compared to traditional mood stabilizer(s) alone in the
maintenance treatment of adolescents with bipolar disorder.
Treatment and Outcome of Early Onset Bipolar Disorder
Completed
Northwell Health
Phase 4
2002-08-01
This study will compare the effectiveness in the maintenance of continuing adjunctive
atypical antipsychotic medication compared to traditional mood stabilizer(s) alone in the
maintenance treatment of adolescents with bipolar disorder.
Study of Outcome and Safety of Lithium, Divalproex and Risperidone for Mania in Children and Adolescents
Completed
National Institute of Mental Health (NIMH)
Phase 3
2003-02-01
This study will evaluate the effectiveness of the medications, lithium (Eskalith®), valproate
(Depakote®), and risperidone (Risperdal®) in treating children and adolescents with bipolar
disorder or symptoms of mania.
Study of Outcome and Safety of Lithium, Divalproex and Risperidone for Mania in Children and Adolescents
Completed
Washington University School of Medicine
Phase 3
2003-02-01
This study will evaluate the effectiveness of the medications, lithium (Eskalith®), valproate
(Depakote®), and risperidone (Risperdal®) in treating children and adolescents with bipolar
disorder or symptoms of mania.
Serving leading biopharmaceutical companies globally:
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.
